Interval Debulking Surgery Is Less Invasive Than Upfront Debulking Surgery for Stage III/IV Cancers (ovarian/PP/FT)

medical news

TAKE-HOME MESSAGE

• In a phase III trial, the standard treatment (primary debulking surgery) was compared with neoadjuvant chemotherapy (including interval debulking surgery) for patients with stage III/IV ovarian, tubal, and peritoneal cancers. Neoadjuvant therapy led to fewer surgeries, reduced operation time, less organ resection, less blood loss, fewer albumin transfusions, and fewer high-grade adverse events following surgery.
  
• Neoadjuvant therapy is less invasive than the standard treatment for advanced ovarian cancer and may become the new standard if noninferiority is confirmed.